Placebo of aspirin

Phase 3

AANRS, Emerging Infectious Diseases

Placebo of aspirin is one of 4 therapeutic programs targeting Tuberculous Meningitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Tuberculous MeningitisRecruiting

Tuberculous MeningitisPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Tuberculous Meningitis

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Phase 3

1 2

WHO TBM Treatment

AANRS, Emerging Infectious Diseases

Phase 3

1 3

Intensified TBM Treatment

AANRS, Emerging Infectious Diseases

Phase 3

1 4

Placebo of aspirin

AANRS, Emerging Infectious Diseases

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Tuberculous Meningitis

NCT04145258

Clinical

Trials by Indication[1]

Tuberculous Meningitis1 trial

Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)

Recruiting·AANRS, Emerging Infectious Diseases·Phase 3·NCT04145258·768 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo of aspirin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo of aspirin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — ANRS, Emerging Infectious Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AANRS, Emerging Infectious Diseases

Placebo of aspirin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Tuberculous Meningitis1 trial

References

Drug Info

Quick Facts

Related News